{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:38Z","timestamp":1793232398040,"version":"4.5.0"},"reference-count":99,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria\u2014even those showing resistance to currently-used fluoroquinolones\u2014and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.<\/jats:p>","DOI":"10.3390\/antibiotics12081241","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T01:51:47Z","timestamp":1690509107000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Updated Review on Clinically-Relevant Properties of Delafloxacin"],"prefix":"10.3390","volume":"12","author":[{"given":"Adrien","family":"Turban","sequence":"first","affiliation":[{"name":"Department of Bacteriology, University Hospital of Rennes, 2 Rue Henri Le Guilloux, 35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-3131","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, University Hospital of Rennes, 2 Rue Henri Le Guilloux, 35000 Rennes, France"},{"name":"UMR_S 1230 BRM, Inserm\/University of Rennes, 2 Avenue du Pr. L\u00e9on Bernard, 35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, University Hospital Raymond Poincar\u00e9, AP-HP, Paris Saclay, Versailles Saint Quentin University, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-9912","authenticated-orcid":false,"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, University Hospital of Rennes, 2 Rue Henri Le Guilloux, 35000 Rennes, France"},{"name":"UMR_S 1230 BRM, Inserm\/University of Rennes, 2 Avenue du Pr. L\u00e9on Bernard, 35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine Derivatives. A New Class Of Chemotherapeutic Agents","volume":"91","author":"Lesher","year":"1962","journal-title":"J. Med. Pharm. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and Safety of Delafloxacin Compared with Vancomycin plus Aztreonam for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Double-Blind, Randomized Study","volume":"72","author":"Pullman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study","volume":"67","author":"McManus","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex. Trans. Dis."},{"key":"ref_5","first-page":"ofz514","article-title":"A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_6","first-page":"1008330","article-title":"Ciprofloxacin-Resistant Pseudomonas Aeruginosa Lung Abscess Complicating COVID-19 Treated with the Novel Oral Fluoroquinolone Delafloxacin","volume":"2022","author":"Panholzer","year":"2022","journal-title":"Case Rep. Pulmonol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2023.01.004","article-title":"Postoperative Linezolid-Resistant Methicillin-Resistant Staphylococcus epidermidis Mediastinitis in a Heart Transplant Patient: First Case of Therapeutic Success with Delafloxacin","volume":"32","author":"Bouchand","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjms.2022.01.016","article-title":"Early Clinical Experience with Delafloxacin: A Case Series","volume":"363","author":"Hornak","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106795","DOI":"10.1016\/j.ijantimicag.2023.106795","article-title":"High-Level Delafloxacin Resistance through the Combination of Two Different Mechanisms in Staphylococcus aureus","volume":"61","author":"Cisneros","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of Delafloxacin against Methicillin-Resistant Staphylococcus aureus: Resistance Selection and Characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In Vitro Activity of Delafloxacin against Clinical Neisseria Gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0028121","DOI":"10.1128\/AAC.00281-21","article-title":"The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia Coli Following Delafloxacin Treatment","volume":"65","author":"Byrd","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Guly\u00e1s, D., Kamotsay, K., Szab\u00f3, D., and Kocsis, B. (2023). Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia Coli Strains and the Detection of E. Coli ST43 International High-Risk Clone. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061602"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone Antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Med. Chem. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","article-title":"Profile of a Novel Anionic Fluoroquinolone-Delafloxacin","volume":"68","author":"Tulkens","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical Structure and Pharmacokinetics of Novel Quinolone Agents Represented by Avarofloxacin, Delafloxacin, Finafloxacin, Zabofloxacin and Nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121506"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/jm0205090","article-title":"A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-Difluorophenyl) Group","volume":"46","author":"Kuramoto","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of Its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy","volume":"10","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting Effects of Acidic PH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","article-title":"Effects of Urine Matrix and PH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia Coli and Klebsiella Pneumoniae","volume":"194","author":"So","year":"2015","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/13543784.2015.1005205","article-title":"Delafloxacin for the Treatment of Respiratory and Skin Infections","volume":"24","author":"Bassetti","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0270521","DOI":"10.1128\/spectrum.02705-21","article-title":"Activity of Delafloxacin and Levofloxacin against Stenotrophomonas Maltophilia at Simulated Plasma and Intrapulmonary PH Values","volume":"10","author":"Vialichka","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Evans-Roberts, K., and Maxwell, A. (2015). DNA Topoisomerases. EcoSal Plus, 6.","DOI":"10.1128\/ecosalplus.ESP-0010-2014"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular Roles of DNA Topoisomerases: A Molecular Perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bmb.20244","article-title":"DNA Topology and Topoisomerases: Teaching a \u201cKnotty\u201d Subject","volume":"37","author":"Deweese","year":"2009","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_29","first-page":"16","article-title":"DNA Gyrase, Topoisomerase IV, and the 4-Quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/AAC.44.8.2160-2165.2000","article-title":"Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis","volume":"44","author":"Fournier","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kakoullis, L., Papachristodoulou, E., Chra, P., and Panos, G. (2021). Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040415"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of Delafloxacin: Focus on Adverse Events of Special Interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alam, P., Iqbal, M., Ezzeldin, E., Khalil, N.Y., Foudah, A.I., Alqarni, M.H., and Shakeel, F. (2020). Simple and Accurate HPTLC-Densitometric Method for Quantification of Delafloxacin (A Novel Fluoroquinolone Antibiotic) in Plasma Samples: Application to Pharmacokinetic Study in Rats. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030134"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jssc.202100768","article-title":"A Novel Liquid Chromatography-Fluorescence Method for the Determination of Delafloxacin in Human Plasma","volume":"45","author":"Hernandis","year":"2021","journal-title":"J. Sep. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical Review of Delafloxacin: A Novel Anionic Fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","article-title":"Single and Multiple Ascending-Dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3109\/00498254.2015.1042946","article-title":"Disposition, Metabolism and Mass Balance of Delafloxacin in Healthy Human Volunteers Following Intravenous Administration","volume":"45","author":"McEwen","year":"2015","journal-title":"Xenobiotica"},{"key":"ref_41","unstructured":"European Medicines Agency (2019). Quofenix (Delafloxacin): Summary of Product Characteristics."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17425255.2017.1386654","article-title":"Clinical and Pharmacokinetic Drug Evaluation of Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","volume":"13","author":"Bassetti","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment","volume":"57","author":"Hoover","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/fmb-2018-0067","article-title":"Delafloxacin: An Improved Fluoroquinolone Developed through Advanced Molecular Engineering","volume":"13","author":"Bassetti","year":"2018","journal-title":"Future Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e02609-16","DOI":"10.1128\/AAC.02609-16","article-title":"In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e01949-19","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus Pneumoniae, Haemophilus Influenzae, and Moraxella Catarrhalis","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e00772-17","DOI":"10.1128\/AAC.00772-17","article-title":"In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jgar.2020.09.027","article-title":"Update on the Activity of Delafloxacin against Acute Bacterial Skin and Skin-Structure Infection Isolates from European Hospitals (2014\u20132019)","volume":"23","author":"Shortridge","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102150","DOI":"10.1016\/j.anaerobe.2020.102150","article-title":"Activity of Delafloxacin versus That of Levofloxacin against Anaerobic and Microaerophilic Isolates","volume":"62","author":"Boyanova","year":"2020","journal-title":"Anaerobe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40265-022-01725-z","article-title":"Delafloxacin: A Review in Community-Acquired Pneumonia","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e00339-18","DOI":"10.1128\/JCM.00339-18","article-title":"Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone","volume":"56","author":"Pfaller","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.47.6.1867-1874.2003","article-title":"Antimicrobial Resistance in Respiratory Tract Streptococcus Pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002","volume":"47","author":"Zhanel","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17512433.2022.2100346","article-title":"A Profile of Delafloxacin in the Treatment of Adults with Community-Acquired Bacterial Pneumonia","volume":"15","author":"Sendra","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms","volume":"48","author":"Almer","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/jac\/dkaa209","article-title":"Delafloxacin Activity against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin or Linezolid","volume":"75","author":"Saravolatz","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e0419022","DOI":"10.1128\/spectrum.04190-22","article-title":"Clinical, Bacteriological, and Genetic Characterization of Bone and Joint Infections Involving Linezolid-Resistant Staphylococcus epidermidis: A Retrospective Multicenter Study in French Reference Centers","volume":"11","author":"Renault","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eimc.2020.09.016","article-title":"In Vitro Activity of Delafloxacin against Highly Levofloxacin-Resistant Invasive Isolates of Streptococcus pneumoniae","volume":"40","author":"Cercenado","year":"2022","journal-title":"Enfermedades Infecc. Microbiol. Cl\u00ednica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"dlad034","DOI":"10.1093\/jacamr\/dlad034","article-title":"The in Vitro Activity of Delafloxacin and Comparator Agents against Bacterial Pathogens Isolated from Patients with Cancer","volume":"5","author":"Gerges","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin\u2014A Novel Fluoroquinolone for the Treatment of Ciprofloxacin-resistant Pseudomonas Aeruginosa in Patients with Cystic Fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin. Respir. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/fmb-2021-0278","article-title":"In Vitro Susceptibility of Nonfermenting Gram-Negative Rods to Meropenem-Vaborbactam and Delafloxacin","volume":"18","author":"Farfour","year":"2023","journal-title":"Future Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e0007921","DOI":"10.1128\/AAC.00079-21","article-title":"Comparison of In Vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria","volume":"65","author":"Wallace","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e0059321","DOI":"10.1128\/AAC.00593-21","article-title":"MIC Distributions of Routinely Tested Antimicrobials and of Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline for Mycobacterium Fortuitum","volume":"65","author":"Chew","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkad015","article-title":"Efficacy of Delafloxacin against the Biothreat Pathogen Bacillus Anthracis","volume":"78","author":"McCurdy","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative Study of the in Vitro Activity of a New Fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2147\/IDR.S142140","article-title":"Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections: Focus on Intravenous Delafloxacin","volume":"11","author":"Righi","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e00099-22","DOI":"10.1128\/spectrum.00099-22","article-title":"In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma Hominis and Ureaplasma Species","volume":"10","author":"Kong","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_71","first-page":"1","article-title":"Fluoroquinolones: Classification, activit\u00e9s antibact\u00e9riennes, r\u00e9sistances et indications th\u00e9rapeutiques","volume":"37","author":"Dejoies","year":"2020","journal-title":"EMC-Mal. Infect."},{"key":"ref_72","unstructured":"Penven, M., and Cattoir, V. (2022). R\u00e9sistance bact\u00e9rienne aux antibiotiques: D\u00e9finitions, m\u00e9canismes et \u00e9volution. EMC-Mal. Infect., 1\u201317."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and Resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Diez-Santos, I., Abbott, L.R., and Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25.","DOI":"10.3390\/molecules25235662"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of Quinolone Action and Resistance: Where Do We Stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1128\/AAC.00274-07","article-title":"Role of a Qnr-like Gene in the Intrinsic Resistance of Enterococcus Faecalis to Fluoroquinolones","volume":"51","author":"Leclercq","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/319370","article-title":"Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones","volume":"32","author":"Hooper","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jac\/dkn136","article-title":"Dual-Targeting Properties of the 3-Aminopyrrolidyl Quinolones, DC-159a and Sitafloxacin, against DNA Gyrase and Topoisomerase IV: Contribution to Reducing in Vitro Emergence of Quinolone-Resistant Streptococcus Pneumoniae","volume":"62","author":"Okumura","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1128\/AAC.49.5.1949-1956.2005","article-title":"Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin","volume":"49","author":"Strahilevitz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","unstructured":"Tow-Keogh, C., McConnell, T., Remy, J., Dalton, J., and DeVito, J.A. (2021, December 08). Anti-MRSA Properties of Delafloxacin: Mutant Analysis and Characterization. Available online: www.melintamedicalinformation.com\/Media\/Publications\/BAXDELA\/ICAAC%202009\/Rib-X_Delafloxacin_ICAAC-2009_C1-1363.pdf."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.49.4.1633-1635.2005","article-title":"Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens","volume":"49","author":"Hermsen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","unstructured":"Remy, J.M., Marra, A., and Duffy, E. (2016, January 16\u201320). Bactericidal Activity of Delafloxacin against Recent Isolates of Staphylococcus aureus. Proceedings of the ASM Microbe 2016, Boston, MA, USA."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e0090322","DOI":"10.1128\/spectrum.00903-22","article-title":"Evaluation of Delafloxacin against a Burkholderia Pseudomallei Efflux Mutant Panel","volume":"10","author":"McCurdy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and Pharmacokinetic Profiling of Delafloxacin in a Murine Lung Model against Community-Acquired Respiratory Tract Pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model","volume":"60","author":"Lepak","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e01131-19","DOI":"10.1128\/AAC.01131-19","article-title":"In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella Pneumoniae and Pseudomonas Aeruginosa in the Neutropenic Murine Pneumonia Model","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","unstructured":"Ding, Y. (2011, January 7\u201310). Treatment of Renal Abscesses Caused by Staphylococcus aureus MW2, Using Delafloxacin and Moxifloxacin. Proceedings of the 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A Randomized Phase 2 Study Comparing Two Doses of Delafloxacin with Tigecycline in Adults with Complicated Skin and Skin-Structure Infections","volume":"30","author":"Mehra","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A Randomized, Double-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1093\/cid\/ciz006","article-title":"Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections","volume":"68","author":"Giordano","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Rusu, A., Munteanu, A.-C., Arb\u0103na\u0219i, E.-M., and Uivarosi, V. (2023). Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030804"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1093\/cid\/ciy1080","article-title":"Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections","volume":"68","author":"Bassetti","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A Thorough QT Study To Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic Penetration into Bone and Joints: An Updated Review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1179\/joc.2007.19.6.682","article-title":"Penetration of Moxifloxacin and Levofloxacin into Cancellous and Cortical Bone in Patients Undergoing Total Hip Arthroplasty","volume":"19","author":"Metallidis","year":"2007","journal-title":"J. Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1439-0272.2003.tb00868.x","article-title":"Antibiotic Therapy\u2014Rationale and Evidence for Optimal Drug Concentrations in Prostatic and Seminal Fluid and in Prostatic Tissue","volume":"35","author":"Naber","year":"2003","journal-title":"Andrologia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fphar.2020.00504","article-title":"Pharmacological Interventions for Bacterial Prostatitis","volume":"11","author":"Xiong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2007.08.025","article-title":"Concentrations of Moxifloxacin in Plasma and Urine, and Penetration into Prostatic Fluid and Ejaculate, Following Single Oral Administration of 400mg to Healthy Volunteers","volume":"31","author":"Wagenlehner","year":"2008","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/8\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:21:11Z","timestamp":1760127671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/8\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":99,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["antibiotics12081241"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12081241","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}